>>NCT00216515
Inclusion Criteria :.
 - Male or female patients aged 50 years or older.
 - Alzheimer's disease according to the criteria of DSM-IV15, NINCDS-ADRDA16.
 - Measuring standard MMSE-K 10 to 26.
 - Patients who are literate.
 - Dementia patients being nursed by the family.
 - Patients who submitted written consent before entering into the clinical trial ( the guardian consent is also effective ).
 Exclusion Criteria :.
 - If the patient was taking AChEI ( Tacrine, Donepezil, Rivastigmine ) to treat dementia, the patient can enter into this clinical trial as long as he/she has not taken the drug within 15 days of the beginning of the clinical trial.
 - Neurodegenerative diseases ( e.g. Parkinson's disease, Pick's disease, Huntington's disease, Down syndrome ).
 - Dementia related to head trauma and dementia related to brain damage due to cerebral hypoxia ( hypoxic brain damage after cardiopulmonary resuscitation, hypoxic brain damage after surgery, hypoxic brain damage due to addiction, hypoxic brain damage due to shock ).
 - brain tumor, nerve syphilis, meningitis, encephalitis, brain tumor.
 - amentia.
 - epilepsy.
 - major psychiatric patients such as major depression and schizophrenia.
 - treatment-resistant gastric and peptic ulcer.
 - patients with clinically serious hepatic, renal, lung, endocrinal or metabolic disease ( thyroid, parathyroid, pituitary, renal failure, diabetes mellitus ).
 - patients complaining of severe difficulty in urination.
 - patients who have undergone heart surgery within 6 months or patients who experienced myocardial infarction, patients with untreated congestive heart failure, patients with severe disorders in the mitral valve or aortic valve.
 - patients who have once taken the investigational drugs within the past 1 month from the beginning day of the clinical trial.
 - patients with uncontrolled diabetes mellitus ( if the patient is taking medication and consults the doctor on a regular basis, he/she can participate in this clinical trial ).
 - patients who experienced hypersensitivity or allergy by a cholinesterase inhibitor.
 - patients who have not given their consent to the clinical trial, patients who are judged inappropriate to participate in this clinical trial by the investigator.

>>NCT02537496
Inclusion Criteria for AD participants :.
 1. Age 55 years or above.
 2. Ability to understand and speak English.
 3. Confirmed Diagnosis of Probable AD by NIA-AA criteria.
 4. Either not taking Cognitive enhancers or taking them at a stable dose for the last 3 months.
 5. Willingness and ability to provide informed consent or an ability to assent and availability of a substitute decision maker willing to provide consent on participant's behalf.
 6. Corrected visual acuity enough to read newspaper headlines.
 7. Ability to hear a raised conversational voice, with hearing aids if needed.
 Inclusion criteria for healthy control participants :.
 1. Age 55 or above.
 2. Willingness and ability to speak English.
 3. Willingness and ability to provide informed consent.
 4. Corrected visual acuity enough to read newspaper headlines.
 5. Ability to hear a raised conversational voice, with hearing aids if needed.
 Exclusion Criteria for AD participants :.
 1. MOCA score < 10.
 2. DSM IV - TR diagnosis of a current episode of mood disorder in the last 3 months.
 3. DSM IV - TR diagnosis of a current anxiety disorder in the last 3 months.
 4. DSM IV - TR diagnosis of a current substance use disorder in the last 3 months.
 5. DSM IV - TR diagnosis of a current or lifetime primary psychotic disorder.
 6. Diagnosis of intellectual disability or a neurodevelopmental disorder.
 7. Electroconvulsive Therapy treatment in the last 6 months.
 8. History of a seizure other than a febrile seizure in infancy.
 9. Currently taking Anticonvulsants or Benzodiazepines.
 10. Any contraindication for TMS or any other medical condition/circumstances that would make the study participation difficult for the participant.
 Exclusion criteria for healthy control participants :.
 1. Meets criteria for a DSM IV - TR diagnosis other than simple phobias or Adjustment disorder.
 2. Any other neurological disorder affecting central nervous system.
 3. Psychotropic medication except for sedative /hypnotics at a stable dose for at least 4 weeks.
 4. History of seizure other than a febrile seizure in infancy.
 5. Currently taking Anticonvulsants or Benzodiazepines.
 6. Any contraindication for TMS or any other medical condition/circumstances that would make the study participation difficult for the participant.

>>NCT00439010
Inclusion Criteria :.
 - The participant is 50 years or older.
 - Written informed consent is obtained.
 - Participants have a clinical diagnosis of Alzheimer's disease based on National Institute of Neurological and Communicative Disorders and Stroke/Alzheimer's Disease and Related Disorders Association ( NINCDS/ADRDA ) criteria.
 - Mini-Mental Status Exam score < 25.
 - Modified Hachinski Ischemia Scale score of <= 4.
 - Geriatric Depression Scales ( GDS ) <= 10.
 - For females, non-child bearing potential or negative urine or blood pregnancy test on day of 123 -I AV39 injection.
 Exclusion Criteria :.
 - The subject has signs or symptoms of another neurodegenerative disease including Parkinson's disease, diffuse Lewy body dementia or history of significant cerebrovascular disease.
 - The subject has a clinically significant abnormal laboratory value and/or clinically significant unstable medical or psychiatric illness.
 - The subject has any disorder that may interfere with drug absorption distribution, metabolism or excretion ( including gastrointestinal surgery ).
 - The subject has evidence of clinically significant gastrointestinal, cardiovascular, hepatic, renal, hematological, neoplastic, endocrine, neurological, immunodeficiency, pulmonary or other disorder or disease.
 - Pregnancy.

>>NCT01928420
Inclusion Criteria :.
 - NINCDS/ADRDA criteria for probable AD.
 - MMSE between 12 - 27.
 - Treatment with a cholinesterase inhibitor or an NMDA ( N-methyl-D-asparate ) antagonist with stable dose for at least 12 weeks.
 - Home monitoring available for supervision of medications.
 - Caregiver available to accompany patient to all visits and willing to participate in study as informant.
 - Fluent in English or Spanish.
 - Medical stability for this study as confirmed by review of records, internist's physical exam, neurological exam and laboratory tests.
 - Stable doses of non-excluded medication.
 - No evidence of hepatic insufficiency.
 - Able to swallow oral medications.
 - Ability to participate in the informed consent process.
 Exclusion Criteria :.
 - History of Diabetes Mellitus ( OGTT criteria ) requiring treatment with an excluded antidiabetic medication ( see below ) or history of hypoglycemia.
 - Active hepatic or renal disease.
 - Cardiac disease including history of congestive heart failure or current treatment for CHF; history of recent myocardial infarction.
 - Use of another investigational drug within the past two months.
 - History of clinically significant stroke.
 - History of seizure or head trauma with disturbance of consciousness within the past two years.
 - Major mental illness including psychotic disorders, bipolar disorder or major depressive episode within the past two years Medication Exclusion.
 - Current use of oral hypoglycemic agents including sulfonylureas and meglintinides.
 - Current or past treatment with insulin for longer than two weeks.
 - Current use of drugs with significant anticholinergic or antihistaminic properties.

>>NCT00948766
Core study.
 Inclusion Criteria :.
 - Diagnosis of probable Alzheimer's disease ( AD ) according to National Institute of Neurological Disorders and Stroke and the Alzheimer's Disease and Related Disorders Association ( NINCDS/ADRDA ) criteria.
 - A Mini-Mental State Examination ( MMSE ) score of >= 3 and <= 12.
 - Be able to complete at least 1 item on the Severe Impairment Battery ( SIB ).
 - Residing with someone in the community or in regular contact with the primary caregiver.
 - Be ambulatory or ambulatory with aid.
 Exclusion Criteria :.
 - An advanced, severe, progressive or unstable disease of any type that may interfere with efficacy and safety assessments or put the patient at special risk.
 - Patients currently residing in a nursing home.
 - Any current medical or neurological condition other than AD that could explain the patient's dementia.
 - A current diagnosis of probable or possible vascular dementia.
 - A current diagnosis of severe or unstable cardiovascular disease.
 - A current diagnosis of bradycardia (< 50 beats per minute [bpm]), sick-sinus syndrome or conduction defects.
 - Clinically significant urinary obstruction.
 - History of malignancy of any organ system within the past 5 years unless patient is verified to be in stable condition with no active metastasis.
 - Current diagnosis of an active skin lesion/disorder that would prevent the patient from using a transdermal patch every day.
 - A known exaggerated pharmacological sensitivity or hypersensitivity to drugs similar to rivastigmine or to other cholinergic compounds.
 - Taken any of the following substances ( at the time of the Baseline Visit [Visit 2]).
 - Succinylcholine-type muscle relaxants during the previous 2 weeks.
 - Lithium during the previous 2 weeks.
 - An investigational drug during the previous 4 weeks.
 - A drug or treatment known to cause major organ system toxicity during the previous 4 weeks.
 - Rivastigmine ( oral or transdermal patch ), donepezil, galantamine, other cholinesterase inhibitors ( eg, tacrine, physostigmine or pyridostigmine ) or other approved treatments for Alzheimer's disease during the previous 2 weeks, with exception of stable treatment with memantine for at least 3 months before study entry ( Visit 1 ).
 - Centrally acting anticholinergic drugs including tricyclic and tetracyclic antidepressants during the previous 4 weeks.
 - Selegiline unless taken at a stable dose during the previous 4 weeks.
 - Peripheral anticholinergics not taken at a stable dose during the previous 4 weeks.
 Extension study.
 Inclusion Criteria :.
 - Complete the double-blind phase ( Week 24 ) of the core study.
 - Provide, if mentally competent, a separate written informed consent prior to participation in the extension study. In addition, the patient's caregiver, will provide written informed consent prior to the patient's participation in the open-label extension study. If the patient is not able to provide written informed consent, written informed consent must be obtained from the legally authorized representative on the patient's behalf.
 - Continue to reside with someone in the community or in regular contact with the primary caregiver; patients who reside in an assisted living facility are eligible to participate.
 - Continue to have a primary caregiver willing to accept responsibility for supervising treatment ( eg, application and removal of the patch daily at approximately the same time of day ), assessing the condition of the patient throughout the extension study.
 - Must be medically stable and tolerating the current dose of rivastigmine patch as determined by the investigator.
 Exclusion Criteria :.
 Refer to the core study protocol for full details of the exclusion criteria.
 - Patients who discontinued the core study due to any reason are excluded.
 - No additional exclusions may be applied by the investigator, in order to ensure that the study population will be representative of all eligible patients.
 Other protocol-defined inclusion/exclusion criteria applied to the study.

>>NCT02073318
Inclusion Criteria :.
 - Patient provides oral consent and written consent obtains from next of kin.
 - Older than 65 years.
 - Diagnosis of dementia, based on Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition ( DSM-IV ) or The International Statistical Classification of Diseases and Related Health Problems 10th Revision ( ICD- 10 ).
 - Can follow order to complete the screening test ( Timed Up and Go test ).
 - Has balance and gait problems.
 - Can standing independently with/without assistive device or can standing with minimal assistance.
 Exclusion Criteria :.
 - Newly developed cardiopulmonary disease and other exercise contraindications.
 - Other neuromuscular or musculoskeletal disease that might affect the outcome ( ex. Recent stroke, fracture or orthopedic surgery ).
